Business
Conversion Notice and Total Voting Rights
Conversion Notice and Total Voting Rights.
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n\n22 July 2024\n \nSkinBioTherapeutics plc\n(\"SkinBioTherapeutics\" or \"the Company\")\n \n \nConversion Notice and Total Voting Rights\n \nSkinBioTherapeutics plc, (AIM: SBTX, or the \"Company\"), the life science business focused on skin health, announces that it received a Conversion Notice on 17 July 2024 from Macquarie (\"Macquarie\") for £160,000 of Convertible Bonds from the £5.0 million convertible bond facility announced on 25 January 2024. The Company has drawn a total of £1,600,000 under the Facility. Following this conversion, the balance of ourstanding bonds will be £480,000.\n \n \nSkinBioTherapeutics will issue 1,989,879 ordinary shares of £0.01 per share (\"Ordinary Shares\") at a conversion price of 8.040687p per Ordinary Share.\n \nAdmission and Total Voting Rights\n \nApplication has been made for the 1,989,879 new ordinary shares, which will rank pari passu in all respects with the existing ordinary shares of the Company, to be admitted to AIM, which is expected to occur on or around 8.00 a.m. on 24 July 2024 (\"Admission\"). Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 205,361,916.\n \nThe above figure of 205,361,916 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.\n \n-Ends-\nThe information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.\n \n \n \n \nFor more information please contact:\n \n\n\n\n\nSkinBioTherapeutics plc\nStuart J. Ashman, CEO\nManprit Randhawa, CFO\n \n \n\n\nTel: +44 (0) 191 495 7325\n \n \n \n\n\n\n\nCavendish Capital Markets Limited\n(Nominated Adviser & Broker)\nGiles Balleny, Dan Hodkinson (Corporate Finance)\nCharlie Combe (Broking)\nDale Bellis, Tamar Cranford-Smith (Sales)\n \n \n\n\nTel: +44 (0) 20 7220 0500\n\n\n\n\nInstinctif Partners (financial press)\nMelanie Toyne-Sewell / Jack Kincade\n\n\nTel: +44 (0) 20 7457 2020\nSk...